Antibody-drug conjugate (ADC) therapy is a proven, revolutionary approach designed to target specific tumor cells with high precision while minimizing toxicity to healthy cells.Good ADC therapy development decisions start with dependable research which translates into accurate, reliable testing protocols and results.Adopting a robust, sensitive, and specific biomarker assay facilitates the correct identification of patients most likely to respond to ADC therapy. This personalized approach allows for selection of predicted responders while avoiding harmful side effects in those unlikely to respond, thus shortening the drug development for this class of compounds.
